Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas
1997

Cyclin A and Lung Cancer Survival

Sample size: 187 publication Evidence: moderate

Author Information

Author(s): M Volm, R Koomagi, J Mattern, G Stammier

Primary Institution: German Cancer Research Centre

Hypothesis

Does cyclin A expression provide additional prognostic value for predicting survival and drug response in patients with non-small-cell lung carcinomas?

Conclusion

Patients with cyclin A-positive lung carcinomas had significantly shorter survival times compared to those with cyclin A-negative carcinomas.

Supporting Evidence

  • 141 out of 187 NSCLCs showed expression of cyclin A.
  • Patients with cyclin A-positive carcinomas had median survival times of 79 weeks.
  • Patients with cyclin A-negative carcinomas had median survival times of 129 weeks.
  • Expression of cyclin A correlated with response to doxorubicin in vitro.

Takeaway

This study found that if a lung cancer patient has cyclin A in their tumor, they might not live as long as someone whose tumor doesn't have cyclin A.

Methodology

Immunohistochemical analysis of formalin-fixed, paraffin-embedded tumor sections from patients with NSCLC.

Potential Biases

Potential bias in patient selection and tumor classification.

Limitations

The study may not account for all clinical parameters influencing survival.

Participant Demographics

187 patients (167 men, 20 women) aged 28 to 76 years, average age 58 years.

Statistical Information

P-Value

0.045

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication